SIRT5 and colorectal carcinoma: SIRT5 expression can be considered a useful CRC prognostic biomarker by affecting chemotherapy in response to FOLFOX regimen (leucovorin, 5-FU and oxaliplatin) and cetuximab treatment (Figure 4) [134].